A comprehensive view of Bristol-Myers Squibb Co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Bristol Myers partners with biotech firm SyntheX to discover, develop, commercialize novel small molecular glue degraders using SyntheX's ToRNeDO platform for protein degradation; SyntheX eligible for up to US$550.0M is milestone payments

AbbVie laying off 99 employees at Irvine, California, manufacturing site; Bristol Myers Squibb laying off 262 employees at two sites in San Diego County, California, one of which was part of BMS’ acquisition of Turning Point Therapeutics in August

Moody's: US drug pricing reform in Inflation Reduction Act may have credit-lowering effect on industry; it’s unclear which drugs costs will get negotiated, but potential candidates include drugs from Bristol Myers, Pfizer, Eli Lilly, AbbVie, J&J, Gilead

Bristol Myers completes acquisition of Turning Point Therapeutics; transaction gives Bristol Myers portfolio of investigational medicines, including next-generation oral drug repotrectinib, that target common mutations associated with oncogenesis

GentiBio collaborating with Bristol Myers to develop engineered T cell therapies to re-establish immune tolerance, repair tissue in inflammatory bowel disease patients; collaboration to produce disease-specific Tregs, take programs into clinical trials

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count